These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

671 related articles for article (PubMed ID: 29844385)

  • 1. CD24 regulates sorafenib resistance via activating autophagy in hepatocellular carcinoma.
    Lu S; Yao Y; Xu G; Zhou C; Zhang Y; Sun J; Jiang R; Shao Q; Chen Y
    Cell Death Dis; 2018 May; 9(6):646. PubMed ID: 29844385
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MiR-21 mediates sorafenib resistance of hepatocellular carcinoma cells by inhibiting autophagy via the PTEN/Akt pathway.
    He C; Dong X; Zhai B; Jiang X; Dong D; Li B; Jiang H; Xu S; Sun X
    Oncotarget; 2015 Oct; 6(30):28867-81. PubMed ID: 26311740
    [TBL] [Abstract][Full Text] [Related]  

  • 3. TARBP2-mediated destabilization of Nanog overcomes sorafenib resistance in hepatocellular carcinoma.
    Lai HH; Li CW; Hong CC; Sun HY; Chiu CF; Ou DL; Chen PS
    Mol Oncol; 2019 Apr; 13(4):928-945. PubMed ID: 30657254
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rage induces hepatocellular carcinoma proliferation and sorafenib resistance by modulating autophagy.
    Li J; Wu PW; Zhou Y; Dai B; Zhang PF; Zhang YH; Liu Y; Shi XL
    Cell Death Dis; 2018 Feb; 9(2):225. PubMed ID: 29445087
    [TBL] [Abstract][Full Text] [Related]  

  • 5. SOCS5 inhibition induces autophagy to impair metastasis in hepatocellular carcinoma cells via the PI3K/Akt/mTOR pathway.
    Zhang M; Liu S; Chua MS; Li H; Luo D; Wang S; Zhang S; Han B; Sun C
    Cell Death Dis; 2019 Aug; 10(8):612. PubMed ID: 31406106
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Increased expression of SLC46A3 to oppose the progression of hepatocellular carcinoma and its effect on sorafenib therapy.
    Zhao Q; Zheng B; Meng S; Xu Y; Guo J; Chen LJ; Xiao J; Zhang W; Tan ZR; Tang J; Chen L; Chen Y
    Biomed Pharmacother; 2019 Jun; 114():108864. PubMed ID: 30981107
    [TBL] [Abstract][Full Text] [Related]  

  • 7. SOX9 enhances sorafenib resistance through upregulating ABCG2 expression in hepatocellular carcinoma.
    Wang M; Wang Z; Zhi X; Ding W; Xiong J; Tao T; Yang Y; Zhang H; Zi X; Zhou W; Huang G
    Biomed Pharmacother; 2020 Sep; 129():110315. PubMed ID: 32554246
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The epigenetically regulated miR-494 associates with stem-cell phenotype and induces sorafenib resistance in hepatocellular carcinoma.
    Pollutri D; Patrizi C; Marinelli S; Giovannini C; Trombetta E; Giannone FA; Baldassarre M; Quarta S; Vandewynckel YP; Vandierendonck A; Van Vlierberghe H; Porretti L; Negrini M; Bolondi L; Gramantieri L; Fornari F
    Cell Death Dis; 2018 Jan; 9(1):4. PubMed ID: 29305580
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Quantitative proteomics identifies FOLR1 to drive sorafenib resistance via activating autophagy in hepatocellular carcinoma cells.
    Chu H; Wu C; Zhao Q; Sun R; Yang K; Zhao B; Liu Y; Liang Z; Zhong S; Zhang L; Zhang Y
    Carcinogenesis; 2021 May; 42(5):753-761. PubMed ID: 33677528
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genome-scale CRISPRa screening identifies MTX1 as a contributor for sorafenib resistance in hepatocellular carcinoma by augmenting autophagy.
    Li L; Yu S; Hu Q; Hai Y; Li Y
    Int J Biol Sci; 2021; 17(12):3133-3144. PubMed ID: 34421355
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Silencing
    Zhu Q; Ren H; Li X; Qian B; Fan S; Hu F; Xu L; Zhai B
    Aging (Albany NY); 2020 Nov; 12(22):22975-23003. PubMed ID: 33203790
    [TBL] [Abstract][Full Text] [Related]  

  • 12. SOD1 inhibition enhances sorafenib efficacy in HBV-related hepatocellular carcinoma by modulating PI3K/Akt/mTOR pathway and ROS-mediated cell death.
    Lee J; Kim J; Lee R; Lee E; An HI; Kwon YJ; Jin H; Pack CG; Kim I; Yoon YI; Park GC; Jwa EK; Kwon JH; Namgoong JM; Song GW; Hwang S; Tak E; Lee SG
    J Cell Mol Med; 2024 Jul; 28(14):e18533. PubMed ID: 39034442
    [TBL] [Abstract][Full Text] [Related]  

  • 13. RNA m
    Lin Z; Niu Y; Wan A; Chen D; Liang H; Chen X; Sun L; Zhan S; Chen L; Cheng C; Zhang X; Bu X; He W; Wan G
    EMBO J; 2020 Jun; 39(12):e103181. PubMed ID: 32368828
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Torin2 overcomes sorafenib resistance via suppressing mTORC2-AKT-BAD pathway in hepatocellular carcinoma cells.
    Hu YT; Shu ZY; Jiang JH; Xie QF; Zheng SS
    Hepatobiliary Pancreat Dis Int; 2020 Dec; 19(6):547-554. PubMed ID: 33051131
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of Akt reverses the acquired resistance to sorafenib by switching protective autophagy to autophagic cell death in hepatocellular carcinoma.
    Zhai B; Hu F; Jiang X; Xu J; Zhao D; Liu B; Pan S; Dong X; Tan G; Wei Z; Qiao H; Jiang H; Sun X
    Mol Cancer Ther; 2014 Jun; 13(6):1589-98. PubMed ID: 24705351
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Glycyrrhizic acid attenuates sorafenib resistance by inducing ferroptosis via targeting mTOR signaling in hepatocellular carcinoma.
    Hu Y; Luo Z; Cai S; Xie Q; Zheng S
    Scand J Gastroenterol; 2024 Jun; 59(6):730-736. PubMed ID: 38426342
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vaccinia-related kinase 2 blunts sorafenib's efficacy against hepatocellular carcinoma by disturbing the apoptosis-autophagy balance.
    Chen S; Du Y; Xu B; Li Q; Yang L; Jiang Z; Zeng Z; Chen L
    Oncogene; 2021 May; 40(19):3378-3393. PubMed ID: 33875785
    [TBL] [Abstract][Full Text] [Related]  

  • 18. IGF2 Is Up-regulated by Epigenetic Mechanisms in Hepatocellular Carcinomas and Is an Actionable Oncogene Product in Experimental Models.
    Martinez-Quetglas I; Pinyol R; Dauch D; Torrecilla S; Tovar V; Moeini A; Alsinet C; Portela A; Rodriguez-Carunchio L; Solé M; Lujambio A; Villanueva A; Thung S; Esteller M; Zender L; Llovet JM
    Gastroenterology; 2016 Dec; 151(6):1192-1205. PubMed ID: 27614046
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting autophagy enhances sorafenib lethality for hepatocellular carcinoma via ER stress-related apoptosis.
    Shi YH; Ding ZB; Zhou J; Hui B; Shi GM; Ke AW; Wang XY; Dai Z; Peng YF; Gu CY; Qiu SJ; Fan J
    Autophagy; 2011 Oct; 7(10):1159-72. PubMed ID: 21691147
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ID1-induced p16/IL6 axis activation contributes to the resistant of hepatocellular carcinoma cells to sorafenib.
    Niu LL; Cheng CL; Li MY; Yang SL; Hu BG; Chong CCN; Chan SL; Ren J; Chen GG; Lai PBS
    Cell Death Dis; 2018 Aug; 9(9):852. PubMed ID: 30154433
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 34.